Want to join the conversation?
Nigel Coe of Morgan Stanley asks for an update on $DHR's Dental segment. CEO Tom Joyce said that the company saw some core improvement in Dental, with 4% core growth. He added that a good part of that growth was around better execution and, to some extent, a little bit easier comp.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?